To pilot the training of scientists at the first PARMA (PMI-supported Antimalarial Resistance Monitoring in Africa) site in Africa in Senegal.

To establish local molecular, genetics and genomic laboratory and analytical capacity to support malaria surveillance in Tanzania.

To scale and integrate genomic epidemiology approaches into real world malaria control and elimination surveillance and decision-making strategy in Senegal, a malaria endemic country.

To collect, manage and analyze data on the safety and efficacy of tafenoquine (Krintafel) used for anti-relapse therapy of malaria in the United States.

To evaluate the feasibility, impact and safety of RTS,S/AS01E malaria vaccine implementation through routine health systems in moderate to high malaria transmission settings in sub-Saharan Africa.